Skip to main
NVAX

Novavax (NVAX) Stock Forecast & Price Target

Novavax (NVAX) Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 38%
Buy 13%
Hold 13%
Sell 25%
Strong Sell 13%

Bulls say

Novavax Inc is experiencing a positive shift in its financial outlook, demonstrated by an increase in its fiscal year 2025 revenue framework, now projected between $1.04 billion and $1.06 billion. The company has recorded $225 million in milestones alongside anticipated earnings of an additional $50 million, indicating strong partnership performance that enhances cash flow and operational funding. Furthermore, Novavax's working capital has improved to $544.7 million, which, combined with reduced expenditures due to cost-saving initiatives, positions the company favorably for future growth and innovation in vaccine development.

Bears say

Novavax Inc. is experiencing notable financial challenges, indicated by a significant decline in cash equivalents from $938.2 million to $778.2 million, attributed to operational cash burn despite receiving milestone payments and proceeds from debt refinancing. The company's year-over-year revenue has decreased by 17%, primarily due to the transfer of lead commercial responsibilities to SNY, which has resulted in reduced commercial infrastructure and a sharp 55% decline in third-quarter revenue. Furthermore, if Novavax's products, such as NanoFlu, do not demonstrate clear differentiation from existing vaccines, the company faces competitive risks that could further hamper its revenue potential and negatively impact future forecasts.

Novavax (NVAX) has been analyzed by 8 analysts, with a consensus rating of Hold. 38% of analysts recommend a Strong Buy, 13% recommend Buy, 13% suggest Holding, 25% advise Selling, and 13% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novavax (NVAX) Forecast

Analysts have given Novavax (NVAX) a Hold based on their latest research and market trends.

According to 8 analysts, Novavax (NVAX) has a Hold consensus rating as of Mar 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novavax (NVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.